Genprex Inc GNPX 深 滬
等待開盤 05-19 09:30:00 美东时间
0.805
-0.025
-3.05%
華盛通- 最 高0.8552
- 今 開0.85
- 成交量 28.43万股
- 最 低 0.791
- 昨 收 0.8303
- 總市值 852.21万
- 52周最高 55.00
- 市盈率 靜 --
- 換手率 2.69%
- 52周最低 0.791
- 委 比 0.17%
- 總股本 1058.64万
- 歷史最高 38900.00
- 量 比 1.12
- 振 幅 7.73%
- 歷史最低 0.791
- 每 手 1
- 風險率 5.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research
05-14 20:06
Genprex Q1 EPS $(0.64) Up From $(13.00) YoY
Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increase over losses of $(13.00) per share from the same period last year.
05-14 05:36
Israel Patent Office Grants Genprex Patent Covering Use Of Reqorsa Gene Therapy In Combination With PD-1 Antibodies For Treatment Of Cancer
Strengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy
04-30 20:08
Genprex Research Collaborators Presents Preclinical Data From Studies Of Lead Drug Candidate, Reqorsa Gene Therapy For Treatment Of Lung Cancer At 2026 AACR Annual Meeting
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell Lines and In Vivo
04-20 19:22
Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers
A Congress member continues to buy small cap stocks. Here's the latest names added to his investment portfolio in March 2026.
03-28 01:10
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR annual meeting
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR annual meeting Genprex said its research collaborators will present preclinical data on Reqorsa gene therapy at the 2026 AACR Annual Meeting on April 17-22, 2026, in San Diego, California. The company said three posters ar
03-18 19:05
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR 2026
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR 2026 Genprex said its collaborators will present preclinical data on Reqorsa (quaratusugene ozeplasmid) for lung cancer at the 2026 AACR Annual Meeting on April 19, 2026. One poster reports that low TROP2 and high PTEN exp
03-18 19:02
Genprex to Participate at BIO Europe Spring 2026
AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies f...
03-10 19:00
Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq®
02-23 21:09
Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies
Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies Genprex Inc. said the Japanese Patent Office issued a favorable appeal decision to grant a patent covering the use of its Reqorsa gene therapy in combination with PD-L1 antibodies t
02-23 21:01
